| Name | 5-ethynyl-1H-pyrimidine-2,4-dione |
|---|---|
| Synonyms |
5-ethynyluracil
Eniluracil (5-Ethynyluracil 5-fluorouracil,cancer,Inhibitor,inhibit,Eniluracil,5-FU,tumor,combination ethynyluracil 5-ETHYNYLURACIL 13C,15N2]-Eniluracil 5-Ethynyluracil> ADH-300004 776C85 5-EthynylpyriMidine-2,4(1H,3H)-dione ethynyluracyl Eniluracil, 10 mM in DMSO BW-776-C85 5-Ethynyl-2,4(1H,3H)-pyriMidinedione Compound 776C 2,4(1H,3H)-Pyrimidinedione, 5-ethynyl 2,4(1H,3H)-Pyrimidinedione, 5-ethynyl- (9CI) GW776C85 5-Ethynyl-1H-pyrimidine-2,4-dione GW-776 PCS-6422 |
| Description | Eniluracil (5-Ethynyluracil), a uracil analogue and a mechanism-based irreversible inhibitor of dihydropyrimidine dehydrogenase (DPD), increases the oral bioavailability of 5-fluorouracil (5-FU) to 100%, facilitating uniform absorption and predictable toxicity[1]. |
|---|---|
| Related Catalog | |
| Target |
Dihydropyrimidine dehydrogenase[1] |
| References |
| Density | 1.39g/cm3 |
|---|---|
| Melting Point | 320 °C(dec.) |
| Molecular Formula | C6H4N2O2 |
| Molecular Weight | 136.10800 |
| Exact Mass | 136.02700 |
| PSA | 65.72000 |
| Index of Refraction | 1.589 |
|
~97%
59989-18-3 |
| Literature: Cooke, Jason W. B.; Bright, Robert; Coleman, Mark J.; Jenkins, Kevin P. Organic Process Research and Development, 2001 , vol. 5, # 4 p. 383 - 386 |
|
~72%
59989-18-3 |
| Literature: Kundu, Nitya G.; Das, Biswajit; Majumdar, Anjali Synthesis, 1990 , # 3 p. 243 - 245 |
|
~%
59989-18-3 |
| Literature: Journal of Heterocyclic Chemistry, , vol. 19, # 3 p. 463 - 464 |
|
~%
59989-18-3 |
| Literature: Journal of Heterocyclic Chemistry, , vol. 19, # 3 p. 463 - 464 |
| Precursor 4 | |
|---|---|
| DownStream 2 | |